Innovative Industrial Properties (IIPR) is considered a strong buy due to its solid balance sheet with low leverage (2.1x debt/EBITDA) providing downside protection amid tenant and sector risks. The rescheduling of medical cannabis has improved tenant credit quality, and the potential rescheduling of recreational cannabis sales is seen as a key future catalyst. Despite sector headwinds and a possible dividend cut, IIPR trades at depressed valuations with significant upside potential. The company’s position in the cannabis real estate market and regulatory developments support its growth outlook.
Innovative Industrial Properties offers a notably high dividend yield of 13.74% on Pluang, where it trades at USD 54.70 as of Nov 06, 2026 22:52 WIB. The stock has seen a 1.08% decrease in the past day and shows a market cap of $1.52 billion. Despite recent selling pressure with 83% of Pluang orders being sell orders, the news highlights potential catalysts from regulatory changes in the cannabis sector that could influence future performance.
Innovative Industrial Properties (IIPR) reported better-than-expected Q3 results, with a 7% increase in AFFO per share driven by successful re-leasing efforts and high-yield life science investments. The company maintains a strong balance sheet with ...
Innovative Industrial Properties (IIPR) announced improved Adjusted Funds From Operations (AFFO) for Q3 2026, indicating some financial progress. However, underlying portfolio trends raise doubts about the long-term sustainability of its earnings, es...
